8-K: Bone Biologics Regains Nasdaq Compliance, Securing Continued Listing

Bone Biologics Corporation announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Summary

• Bone Biologics Corporation received a letter from The Nasdaq Stock Market LLC on June 25, 2025, confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
• This rule requires listed companies to maintain a minimum bid price of at least $1 per share.
• The Company was initially notified of non-compliance on April 7, 2025, because its common stock failed to meet the $1.00 closing bid price for 30 consecutive business days.
• To regain compliance, Bone Biologics was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.
• This requirement was met on June 24, 2025, which was the 10th consecutive trading day the common stock's closing bid price was over $1.00.
• Bone Biologics is now in compliance with all applicable listing standards, and its common stock (BBLG) and warrants (BBLGW) will continue to be listed on the Nasdaq Capital Market.

Sentiment

Score: 8

Explanation: The company successfully resolved its Nasdaq minimum bid price non-compliance, ensuring continued listing and removing a major overhang for investors. This is a significant positive development for the company's market standing.

Positives

• Successfully regained compliance with Nasdaq Listing Rule 5550(a)(2), ensuring continued listing on the Nasdaq Capital Market.
• Averted potential delisting from Nasdaq, removing a significant overhang for investors.
• The Company's common stock maintained a closing bid price of over $1.00 for 10 consecutive trading days, demonstrating price stability above the minimum threshold.

Negatives

• The Company was previously non-compliant with Nasdaq's minimum bid price rule, indicating past share price weakness that led to the compliance issue.

Risks

• The inherent risk of failing to maintain Nasdaq listing standards, which was previously present due to the minimum bid price deficiency but has now been resolved.

Future Outlook

The document primarily focuses on the resolution of the Nasdaq listing compliance issue. It reiterates Bone Biologics' ongoing development efforts for its bone graft substitute product, focusing on bone regeneration in spinal fusion procedures, with additional rights for trauma and osteoporosis applications.

Management Comments

• "Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on the Nasdaq Capital Market."

Industry Context

Maintaining a listing on a major exchange like Nasdaq is critical for small-cap biotechnology and medical device companies like Bone Biologics, as it provides access to capital markets, enhances liquidity for investors, and maintains corporate visibility. The orthobiologics and spine fusion market is a specialized segment within the broader healthcare industry, where regulatory compliance and market access are paramount.

Stakeholder Impact

• Shareholders: Positive impact as the risk of delisting is removed, maintaining liquidity and visibility for their investment.
• Employees: Stability in the company's public listing status can provide a more secure and stable corporate environment.
• Customers/Partners: Continued listing enhances the company's credibility and ability to operate and secure future collaborations.

Next Steps

• Continued development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures.
• Pursuit of trauma and osteoporosis applications for its bone graft substitute product.

Key Dates

Recommendation

Keywords

Bone Biologics, BBLG, Nasdaq, Listing Compliance, Minimum Bid Price, Orthobiologics, Spine Fusion, Regenerative Medicine, NELL-1 protein, Medical Devices